CYP46A1 — Cholesterol 24-Hydroxylase

CYP46A1 — Cholesterol 24-Hydroxylase

Overview

Cyp46A1 — Cholesterol 24 Hydroxylase plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Pathway Diagram

CYP46A1 — Cholesterol 24-Hydroxylase

Overview

Cyp46A1 — Cholesterol 24 Hydroxylase plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Pathway Diagram

Introduction

Cyp46A1 — Cholesterol 24 Hydroxylase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@ncbi]

The CYP46A1 gene encodes cholesterol 24-hydroxylase, a enzyme expressed primarily in [neurons](/entities/neurons) of the brain that catalyzes the conversion of cholesterol to 24-hydroxycholesterol. This enzyme is the key player in cholesterol elimination from the brain, as 24-hydroxycholesterol can cross the [blood-brain barrier](/entities/blood-brain-barrier) for peripheral clearance. Genetic variations in CYP46A1 have been associated with an increased risk of [Alzheimer's disease](/diseases/alzheimers-disease), making it an important therapeutic target.

Gene Overview

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">CYP46A1</th></tr>
<tr><td><b>Full Name</b></td><td>Cholesterol 24-Hydroxylase</td></tr>
<tr><td><b>Chromosome</b></td><td>14</td></tr>
<tr><td><b>Location</b></td><td>14q13.3</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[10585](https://www.ncbi.nlm.nih.gov/gene/10585)</td></tr>
<tr><td><b>OMIM</b></td><td>[604673](https://www.omim.org/entry/604673)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>[ENSG00000146386](https://www.ensembl.org/Human/Gene/Summary?g=ENSG00000146386)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9Y3D5](https://www.uniprot.org/uniprotkb/Q9Y3D5/entry)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer_disease" style="color:#ef9a9a">ALZHEIMER_DISEASE</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/dravet_syndrome" style="color:#ef9a9a">DRAVET_SYNDROME</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-2600483e" style="color:#ce93d8" title="Score: 0.61">CYP46A1 Overexpression Gene Therapy...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">107 edges</a></td>
</tr>
</table>
</div>

Function

CYP46A1 plays a critical role in cholesterol metabolism, which is intimately connected to Alzheimer's disease pathogenesis through multiple mechanisms:

Role in Cholesterol Homeostasis

• Regulates cholesterol biosynthesis and uptake
• Maintains neuronal membrane composition
• Influences synaptic function and plasticity
• Modulates amyloid precursor protein (APP) processing

Brain Cholesterol Metabolism

The brain contains approximately 25% of the body's cholesterol but is isolated from peripheral cholesterol by the blood-brain barrier. Key mechanisms include:

• Local cholesterol synthesis in neurons and glia
• CYP46A1-mediated 24-hydroxylation for efflux
• ApoE-mediated cholesterol transport
• LDLR-mediated uptake

Disease Associations

Alzheimer's Disease

| Mechanism | Effect |
|-----------|--------|
| Altered cholesterol metabolism | Increases [Aβ](/proteins/amyloid-beta) production |
| Dysregulated APP processing | Enhances amyloidogenesis |
| Impaired synaptic cholesterol | Defects in neurotransmission |
| Oxidative stress | Neuronal vulnerability |

Other Associated Conditions

| Disease | Relationship |
|---------|-------------|
| Alzheimer's Disease | Primary association |
| Cognitive Impairment | Secondary complication |
| Cardiovascular disease | Comorbidity |

Therapeutic Implications

Statins and AD

HMGCR inhibitors (statins) have been studied extensively in AD:

• Observational studies suggest reduced AD risk with statin use
• Clinical trials have shown mixed results
• Lipophilic statins may be more effective due to brain penetration

Future Directions

• CYP46A1 activation for enhanced cholesterol efflux
• SREBP-2 modulators
• LDLR-targeted therapies
• Combination approaches targeting multiple pathways

Expression

The CYP46A1 gene shows distinct expression patterns:

• Brain: Primary expression in neurons and [astrocytes](/entities/astrocytes)
• Liver: High expression for systemic cholesterol regulation
• Peripheral tissues: Variable expression

Key Publications

Overview

Cyp46A1 — Cholesterol 24 Hydroxylase plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Cyp46A1 — Cholesterol 24 Hydroxylase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Cross-References

• [Cholesterol Metabolism in AD](/mechanisms/cholesterol-metabolism-alzheimers)
• [APOE Gene](/proteins/apoe) - [Apolipoprotein E](/proteins/apoe)
• [Lipid Rafts and Neurodegeneration](/mechanisms/lipid-rafts-neurodegeneration)
• [Amyloid Precursor Protein](/entities/app-protein)

See Also

• [Genes/Cyp46A1](/genes/cyp46a1) — This page

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CYP46A1

Pathway Diagram

The following diagram shows the key molecular relationships involving CYP46A1 — Cholesterol 24-Hydroxylase discovered through SciDEX knowledge graph analysis:

<!-- scidex-demo:links:start -->

SciDEX Links

Related Hypotheses

• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — score 0.92; target CYP46A1; neurodegeneration.
• [APOE Isoform Expression Across Glial Subtypes](/hypothesis/h-seaad-fa5ea82d) — score 0.74; target APOE; Alzheimer's Disease.
• [APOE Isoform Conversion Therapy](/hypothesis/h-15336069) — score 0.72; target APOE; neurodegeneration.
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — score 0.72; target APOE, LRP1, LDLR; neurodegeneration.

Related Analyses

• [Lipid raft composition changes in synaptic neurodegeneration](/analyses/SDA-2026-04-01-gap-lipid-rafts-2026-04-01)
• [Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analyses/SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402)
• [APOE4 structural biology and therapeutic targeting strategies](/analyses/SDA-2026-04-01-gap-010)